Status:
COMPLETED
OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -
Lead Sponsor:
Karen-Lise Garm Spindler
Conditions:
Colorectal Cancer Metastatic
Circulating Tumor DNA
Eligibility:
All Genders
18+ years
Brief Summary
The present study will investigate the feasibility and clinical value of using circulating tumor DNA as selection for anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.
Detailed Description
The primary aim of this prospective study is to investigate if cfDNA in plasma is feasible and reliable for selection of mCRC patients who will benefit of anti-EGFR monoclonal antibody therapy Second...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Histopathologically verified metastatic colorectal cancer
- Indication for systemic palliative treatment with standard Anti-EGFR monoclonal antibodies
- Fit for therapy with EGFR inhibition
- Consent to treatment and sampling
- Measureable disease according to RECIST v 1.1
- Age ≥ 18
- Exclusion criteria
- PS \> 2
- Significant other cancer disease within 5 years of inclusion
- Conditions precluding sampling during therapy and treatment breaks.
Exclusion
Key Trial Info
Start Date :
June 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT03750175
Start Date
June 1 2018
End Date
December 31 2022
Last Update
February 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Denmark, 8000